TruScreen Investor Briefing

TruScreen Investor Briefing Cervical cancer technology company, TruScreen Limited (NZAX:TRU), advises that it wishes to provide to shareholders a copy of its latest investor briefing presentation. Please find attached a copy of the presentation, or you may download a copy at http://truscreen.com/investor-centre/reports-presentations/. ENDS For more information visit www.truscreen.com Contact: Martin Dillon, TruScreen Chief Executive Officer email: martindillon@truscreen.com About TruScreen: TruScreen real time cervical cancer technology utilises a digital wand which is placed on the surface of the cervix to measure electrical and optical signals from the surrounding tissue to identify precancerous change, or cervical intraepithelial neoplasia (CIN).TruScreen has distribution contracts in a range of international markets, including China, Latin America, Central Asia, Russia, the Middle East and Eastern Europe. -ENDS- End CA:00297920 For:TRU Type:ADDRESS Time:2017-03-07 10:37:20